FI20010620A0 - Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa - Google Patents

Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa

Info

Publication number
FI20010620A0
FI20010620A0 FI20010620A FI20010620A FI20010620A0 FI 20010620 A0 FI20010620 A0 FI 20010620A0 FI 20010620 A FI20010620 A FI 20010620A FI 20010620 A FI20010620 A FI 20010620A FI 20010620 A0 FI20010620 A0 FI 20010620A0
Authority
FI
Finland
Prior art keywords
liposomes
matrix metalloproteinase
metalloproteinase inhibitors
tumor cells
cells
Prior art date
Application number
FI20010620A
Other languages
English (en)
Swedish (sv)
Other versions
FI113840B (fi
FI20010620A (fi
Inventor
Medina Oula Penate
Erkki Koivunen
Paavo Kinnunen
Original Assignee
Licentia Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licentia Oy filed Critical Licentia Oy
Publication of FI20010620A0 publication Critical patent/FI20010620A0/fi
Priority to FI20010620A priority Critical patent/FI113840B/fi
Priority to PCT/FI2002/000252 priority patent/WO2002076491A1/en
Priority to PL02365248A priority patent/PL365248A1/xx
Priority to JP2002575004A priority patent/JP2004529127A/ja
Priority to AT02706813T priority patent/ATE331526T1/de
Priority to IL15811402A priority patent/IL158114A0/xx
Priority to CZ20032805A priority patent/CZ20032805A3/cs
Priority to US10/471,980 priority patent/US20040213833A1/en
Priority to HU0303649A priority patent/HUP0303649A3/hu
Priority to EP02706813A priority patent/EP1372694B1/en
Priority to SK1298-2003A priority patent/SK12982003A3/sk
Priority to ES02706813T priority patent/ES2266458T3/es
Priority to NZ528043A priority patent/NZ528043A/en
Priority to YU74703A priority patent/YU74703A/sh
Priority to RU2003131332/15A priority patent/RU2003131332A/ru
Priority to KR10-2003-7012506A priority patent/KR20040000414A/ko
Priority to BR0208681-6A priority patent/BR0208681A/pt
Priority to EEP200300467A priority patent/EE200300467A/xx
Priority to CNB028073118A priority patent/CN1250279C/zh
Priority to DK02706813T priority patent/DK1372694T3/da
Priority to CA002441227A priority patent/CA2441227A1/en
Priority to DE60212814T priority patent/DE60212814T2/de
Publication of FI20010620A publication Critical patent/FI20010620A/fi
Priority to NO20034280A priority patent/NO20034280L/no
Application granted granted Critical
Publication of FI113840B publication Critical patent/FI113840B/fi
Priority to US11/125,186 priority patent/US20050271588A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI20010620A 2001-03-26 2001-03-26 Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa FI113840B (fi)

Priority Applications (24)

Application Number Priority Date Filing Date Title
FI20010620A FI113840B (fi) 2001-03-26 2001-03-26 Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa
NZ528043A NZ528043A (en) 2001-03-26 2002-03-26 Use of peptides CTTHWGFTLC, CLPGHWGFPSC and STTHWGFTLS in enhancing targeting and uptake of liposome containing chemotherapeutic agents to tumor cells to treat cancer and its use in diagnostics
RU2003131332/15A RU2003131332A (ru) 2001-03-26 2002-03-26 Липосомное нацеливание ингибиторов матриксной металлопротеиназы
JP2002575004A JP2004529127A (ja) 2001-03-26 2002-03-26 マトリックス金属プロティナーゼ阻害物質を用いたリポソームターゲッティング
AT02706813T ATE331526T1 (de) 2001-03-26 2002-03-26 Liposomen-targeting von matrix-metalloproteinase- hemmern
IL15811402A IL158114A0 (en) 2001-03-26 2002-03-26 Liposome targeting of matrix metalloproteinase inhibitors
CZ20032805A CZ20032805A3 (cs) 2001-03-26 2002-03-26 Použití peptidových sloučenin, způsob zlepšení směrování a absorpce lipozómů, způsob léčby a diagnostiky pacientů, diagnostická nebo zobrazovací testovací sada a přípravek
US10/471,980 US20040213833A1 (en) 2001-03-26 2002-03-26 Liposomes targeting of matrix metalloproteinase inhibitors
HU0303649A HUP0303649A3 (en) 2001-03-26 2002-03-26 Liposome targeting of matrix metalloproteinase inhibitors
EP02706813A EP1372694B1 (en) 2001-03-26 2002-03-26 Liposome targeting of matrix metalloproteinase inhibitors
SK1298-2003A SK12982003A3 (sk) 2001-03-26 2002-03-26 Použitie peptidových zlúčenín, spôsob zlepšenia smerovania a absorpcie lipozómov, spôsob liečby a diagnostiky pacientov, diagnostická alebo zobrazovacia súprava a prostriedok
ES02706813T ES2266458T3 (es) 2001-03-26 2002-03-26 Transporte dirigido de liposomas de inhibidores de metaloproteinasas de matriz.
PCT/FI2002/000252 WO2002076491A1 (en) 2001-03-26 2002-03-26 Liposome targeting of matrix metalloproteinase inhibitors
YU74703A YU74703A (sh) 2001-03-26 2002-03-26 Lipozomsko ciljanje inhibitora mreže metaloproteinaze
PL02365248A PL365248A1 (en) 2001-03-26 2002-03-26 Liposome targeting of matrix metalloproteinase inhibitors
KR10-2003-7012506A KR20040000414A (ko) 2001-03-26 2002-03-26 매트릭스 메탈로프로테이나제 저해제의 리포좀 표적화
BR0208681-6A BR0208681A (pt) 2001-03-26 2002-03-26 Compostos de peptìdeos e uso dos mesmos
EEP200300467A EE200300467A (et) 2001-03-26 2002-03-26 Liposoomide suunamine maatriksi metalloproteinaaside inhibiitorite abil
CNB028073118A CN1250279C (zh) 2001-03-26 2002-03-26 基质金属蛋白酶抑制剂的脂质体靶向
DK02706813T DK1372694T3 (da) 2001-03-26 2002-03-26 Liposom-målretning af matrix-metalloproteinase-hæmmere
CA002441227A CA2441227A1 (en) 2001-03-26 2002-03-26 Liposome targeting of matrix metalloproteinase inhibitors
DE60212814T DE60212814T2 (de) 2001-03-26 2002-03-26 Liposomen-targeting von matrix-metalloproteinase-hemmern
NO20034280A NO20034280L (no) 2001-03-26 2003-09-25 Liposommålretting av matrise metallproteinasehemmere
US11/125,186 US20050271588A1 (en) 2001-03-26 2005-05-10 Liposome targeting of matrix metalloproteinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20010620A FI113840B (fi) 2001-03-26 2001-03-26 Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa
FI20010620 2001-03-26

Publications (3)

Publication Number Publication Date
FI20010620A0 true FI20010620A0 (fi) 2001-03-26
FI20010620A FI20010620A (fi) 2002-09-27
FI113840B FI113840B (fi) 2004-06-30

Family

ID=8560842

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20010620A FI113840B (fi) 2001-03-26 2001-03-26 Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa

Country Status (23)

Country Link
US (2) US20040213833A1 (fi)
EP (1) EP1372694B1 (fi)
JP (1) JP2004529127A (fi)
KR (1) KR20040000414A (fi)
CN (1) CN1250279C (fi)
AT (1) ATE331526T1 (fi)
BR (1) BR0208681A (fi)
CA (1) CA2441227A1 (fi)
CZ (1) CZ20032805A3 (fi)
DE (1) DE60212814T2 (fi)
DK (1) DK1372694T3 (fi)
EE (1) EE200300467A (fi)
ES (1) ES2266458T3 (fi)
FI (1) FI113840B (fi)
HU (1) HUP0303649A3 (fi)
IL (1) IL158114A0 (fi)
NO (1) NO20034280L (fi)
NZ (1) NZ528043A (fi)
PL (1) PL365248A1 (fi)
RU (1) RU2003131332A (fi)
SK (1) SK12982003A3 (fi)
WO (1) WO2002076491A1 (fi)
YU (1) YU74703A (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
IL152609A0 (en) * 2002-11-03 2003-06-24 Hapto Biotech Inc Liposomal compositions comprising haptotactic peptides and uses thereof
CN1314704C (zh) * 2002-11-20 2007-05-09 中国人民解放军军事医学科学院放射与辐射医学研究所 基质金属蛋白酶2的小肽抑制剂
EP1594550A4 (en) * 2003-01-24 2007-07-11 Barnes Jewish Hospital CHELATBILDNER WITH LIPOPHILES
FI115035B (fi) * 2003-05-02 2005-02-28 Ctt Cancer Targeting Tech Oy In vivo -kuvantaminen käyttäen peptidijohdannaisia
FI20031528A0 (fi) * 2003-10-17 2003-10-17 Ctt Cancer Targeting Tech Oy Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi
FI20040572A0 (fi) * 2004-04-23 2004-04-23 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasin aktiviteetin inhibiittorit
FI20040682A0 (fi) * 2004-05-14 2004-05-14 Ctt Cancer Targeting Tech Oy Tuumorien ja mestastaasien kuvantaminen käyttäen gelatinaasiin targetoituvaa peptidiä
FR2870741B1 (fr) 2004-05-25 2008-03-14 Coletica Sa Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant.
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CN101616692B (zh) * 2006-07-06 2013-05-08 纽约市哥伦比亚大学信托人 用于血管造影术的多色的不同大小的颗粒
CN102114000B (zh) * 2009-12-31 2013-08-21 复旦大学 一种载药的共输送脂质纳米递药系统
US8871189B2 (en) * 2011-11-30 2014-10-28 Mallinckrodt Llc MMP-targeted therapeutic and/or diagnostic nanocarriers
US11339209B2 (en) 2016-11-14 2022-05-24 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158760A (en) * 1990-05-30 1992-10-27 Board Of Regents, The University Of Texas System 99m TC labeled liposomes
IL130823A (en) * 1996-10-15 2005-12-18 Elan Pharm Inc Peptide-lipid conjugates, liposomes drug delivery
FI980604A0 (fi) * 1998-03-18 1998-03-18 Univ Helsinki Licensing Nya matrismetalloproteinasinhibitorer och -regulatorer

Also Published As

Publication number Publication date
NO20034280L (no) 2003-11-25
WO2002076491A1 (en) 2002-10-03
CA2441227A1 (en) 2002-10-03
DK1372694T3 (da) 2006-10-30
US20040213833A1 (en) 2004-10-28
FI113840B (fi) 2004-06-30
ES2266458T3 (es) 2007-03-01
CZ20032805A3 (cs) 2004-06-16
EP1372694B1 (en) 2006-06-28
US20050271588A1 (en) 2005-12-08
ATE331526T1 (de) 2006-07-15
DE60212814T2 (de) 2007-02-08
CN1250279C (zh) 2006-04-12
EE200300467A (et) 2003-12-15
KR20040000414A (ko) 2004-01-03
NZ528043A (en) 2005-08-26
DE60212814D1 (de) 2006-08-10
CN1531439A (zh) 2004-09-22
EP1372694A1 (en) 2004-01-02
BR0208681A (pt) 2004-03-30
HUP0303649A2 (hu) 2004-01-28
PL365248A1 (en) 2004-12-27
IL158114A0 (en) 2004-03-28
RU2003131332A (ru) 2005-04-10
JP2004529127A (ja) 2004-09-24
HUP0303649A3 (en) 2005-12-28
SK12982003A3 (sk) 2004-08-03
NO20034280D0 (no) 2003-09-25
FI20010620A (fi) 2002-09-27
YU74703A (sh) 2006-05-25

Similar Documents

Publication Publication Date Title
FI20010620A0 (fi) Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa
WO2003002595A3 (en) Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
EA200800268A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
PL1631295T3 (pl) Zastosowanie skondensowanych związków heterocyklicznych jako inhibitorów SCCE do leczenia chorób skóry
CY1110329T1 (el) Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743
HUP0402656A2 (hu) Sejtterápiás eljárás tumorok kezelésére
ATE439134T1 (de) Medikament zum schutz in der radiotherapie
EA200300934A1 (ru) Агенты и способы, предназначенные для лечения опухолевых заболеваний
AU2001272017A1 (en) Targeted combination immunotherapy of cancer and infectious diseases
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
RS52668B (en) ANTITUMOR EFFECT, ANTI-TUMOR AND ANALYSIS PROCESS
TW200724158A (en) Combination therapy in the treatment of cancer
ATE313334T1 (de) Behandlung von tumoren mit photodynamischer therapie
WO2003106640A3 (en) CELL TARGETING METHODS AND COMPOSITIONS
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
DE60331827D1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
SE0100684D0 (sv) New subject-matter
WO2002074756A3 (de) Urokinase-inhibitoren
CY1106363T1 (el) Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων
WO2005030225A3 (en) Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers
HUP0301276A2 (hu) Kombinációs terápia ösztrogénérzékeny betegségek kezelésére
WO2003053999A3 (de) Selektive arylguanidinpeptide als urokinaseinhibitoren
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)